02.12.2019 Issue 438

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

ICER Sets Out Against Unjustified
Price Increases in New Report

Thursday, February 7

ICER is targeting unjustified price increases as it looks to expand its focus beyond quality-adjust life year analysis, Pharmaceutical Executive reports.

IQVIA’s Doyle Talks Shared Value Across All Stakeholders

Leonard Discusses NPC’s Response to HHS RFI

Tufts Medical Center Announces New Center

Analysis Suggests Income Correlated to Filled Prescriptions

HealthEconomics.Com Announces New Rate for Job Listings

J&J to Include List Prices in TV Ads

Podcast Talks Operationalizing Innovation


Provider Contract/Cost of Care Consultant Sr - PS16029

Medical Statistician

Medical Writer / Literature Review Scientist

Senior Health Economics & Real-World Evidence (HE-RWE) Scientist

Industry Spotlight


Conferences Webinars
Paying for Cures: Ensuring Patient Access and System Sustainability
    February 12, Washington, D.C.

MRC training workshop on Health Economics Analysis Plans
    February 14, Bristol, England

18th Annual International Publication Planning Meeting
    February 20-21, San Diego, California

12th Annual Oncology Market Access Strategy Summit
    February 20-21, San Francisco, California

Precision Medicine for Health Plans
    February 13

Enhancing Your Professional Brand with LinkedIn
    February 13

Clinical Statistics for Non-Statisticians
    February 27

Is the New Congress Ready to Lower Drug Costs?
    February 27


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

HTA in Europe: Key Success Factors for Positive HTA Recommendations

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
               Truven            
          Evidera    HealthCore    University of FL   Xcenda
      OM1    Parexel    Jefferson    Dymaxium   Precision Xtract    
      Pharmerit    eMax Health    Sciformix   Evidence Partners    ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn